Stemline Therapeutics, Inc.
Clinical trials sponsored by Stemline Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for advanced breast cancer in early trial Results expected Nov 2026 (estimated)
- New hope for breast cancer patients with brain tumors: drug combo trial underway Results expected Dec 2026 (estimated)
- New drug cocktails aim to stall metastatic breast cancer Results expected Dec 2026 (estimated)
- Can chemotherapy tame a rare blood cancer? a look back at Real-World outcomes Results expected May 2027 (estimated)
-
New hope for breast cancer patients with brain tumors: drug combo trial underway
Disease control Recruiting nowThis study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …
Phase 1/2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Can a targeted therapy tame a rare blood cancer in everyday practice?
Disease control Recruiting nowThis registry study is following adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, who are being treated with the drug tagraxofusp (ELZONRIS) in routine clinical care. The goal is to see how effective the treatment is at achievi…
Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new pill outsmart resistant breast cancer?
Disease control Recruiting nowThis trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elace…
Phase 2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to stop breast cancer from coming back in high-risk patients
Disease control Recruiting nowThis study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer (ER+/HER2-) that has spread to lymph nodes and has a high chance of returning. About 4,220 participants will be randomly assigned to receive either…
Phase 3 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for advanced breast cancer: first human trial of MEN2312 begins
Disease control Recruiting nowThis early-stage trial tests a new drug called MEN2312, alone or with another drug (elacestrant), in 240 adults with advanced breast cancer that has specific genetic changes. The main goals are to find a safe dose and check for side effects. It is the first time MEN2312 is being …
Phase 1 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for tough ovarian cancer: first human trial of MEN2501 launches
Disease control Recruiting nowThis early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum chemotherapy. The main goals are to check safety and find the best dose. Researchers will also watch for signs that the drug shrinks tumors or sl…
Phase 1 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can chemotherapy tame a rare blood cancer? a look back at Real-World outcomes
Knowledge-focused Recruiting nowThis study looks back at the medical records of about 140 people with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received chemotherapy as their first treatment. The goal is to see how effective and safe different chemotherapy regimens are …
Sponsor: Stemline Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC